Sep 18, 2026•3 min read
Mirae Asset Report Shows Korean Pharma & Bio Firms Strengthening Fundamentals Amid Market Weakness
Despite short‑term stock pressure from interest rates and supply issues, Korean pharma and biotech companies are pursuing M&A, tech exports and capacity investments, boosting fundamentals, says a Mirae Asset report.